The Myeloproliferative Neoplasms Channel on VJHemOnc is an independent medical education platform, supported with funding from Takeda (Gold) and Kartos Therapeutics, Inc. (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
MPN Workshop of the Carolinas 2025 | Inflammation and MPNs: targeting inflammation throughout the disease course
In this video, Stephen Oh, MD, PhD, Washington University School of Medicine, St. Louis, MO, briefly discusses a session at the 2025 MPN Workshop of the Carolinas, which focused on inflammation and myeloproliferative neoplasms (MPN). Prof. Oh highlights that targeting aberrant inflammation may be important throughout the disease course in MPNs, from the early stages of disease through to disease progression. This interview took place at the 2nd Annual MPN Workshop of the Carolinas, held in Charlotte, NC.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Transcript
Yeah, so we had a really great session with four talks broadly focused on the role of inflammation in MPNs. And this is a concept that’s been studied by a number of investigators in the field, both in the laboratory and on the clinical side for a number of years. And I think, you know, really importantly, this is a concept that applies to the earliest stages of this disease, including in the setting of clonal hematopoiesis, all the way through to the chronic MPN disease stages, and through to disease progression...
Yeah, so we had a really great session with four talks broadly focused on the role of inflammation in MPNs. And this is a concept that’s been studied by a number of investigators in the field, both in the laboratory and on the clinical side for a number of years. And I think, you know, really importantly, this is a concept that applies to the earliest stages of this disease, including in the setting of clonal hematopoiesis, all the way through to the chronic MPN disease stages, and through to disease progression. So we’re thinking very carefully about when and how to target aberrant inflammation in these diseases early on, as well as later in disease development.
This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.
Read more...
